Related Experiment Videos
Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy
1Department of Medicine, University of Göteborg, Ostra Hospital, Sweden.
Insights
Angiotensin-converting enzyme (ACE) inhibitors effectively reverse left ventricular hypertrophy (LVH) and cardiac fibrosis associated with hypertension. This therapeutic goal is crucial for reducing cardiovascular disease risk.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular disease, often resulting from hypertension.
- The renin-angiotensin system plays a key role in the development of LVH and cardiac fibrosis.
- Reversing LVH is a critical therapeutic objective in managing hypertension.
Purpose of the Study:
- To investigate the efficacy of angiotensin-converting enzyme (ACE) inhibitors in reversing LVH.
- To evaluate the role of ACE inhibition in mitigating cardiac structural changes and fibrosis.
- To compare the effects of ACE inhibitors with other antihypertensive agents on LVH.
Main Methods:
- Review of experimental and human studies on ACE inhibitors and LVH.
- Analysis of meta-analyses comparing ACE inhibitors with other antihypertensives.
- Examination of controlled studies, including long-term trials, assessing LVH regression.
- Exploration of studies investigating ACE inhibitors' effects independent of blood pressure reduction.
Main Results:
- ACE inhibitors demonstrate superior efficacy in reversing LVH compared to other antihypertensive drugs.
- Studies show ACE inhibitors reduce left ventricular mass more effectively than first-line alternatives.
- Enalapril significantly reversed LVH in untreated men, outperforming hydrochlorothiazide.
- LVH regression was linked to renin-angiotensin system blockade, with potential effects independent of blood pressure reduction.
- ACE inhibitors exhibit cardioprotective and cardioreparative effects in experimental models.
Conclusions:
- ACE inhibitors are effective in reversing left ventricular hypertrophy and cardiac interstitial fibrosis.
- The prognostic significance of these findings requires further investigation.
- While experience with specific agents like spirapril is limited, current data on ACE inhibitors for LVH are promising.
Abstract:
Left ventricular hypertrophy (LVH) is a recognized complication of, rather than a physiological response to, hypertension, being a powerful independent indicator of cardiovascular disease risk. In addition, it is reasonable to assume that the reversal of LVH is a desirable therapeutic goal in the treatment of hypertension. Furthermore, the renin-angiotensin system plays an important role in LVH and, in particular, in the development of cardiac interstitial fibrosis. Therefore, the effect of angiotensin-converting enzyme (ACE) inhibition on LVH is of particular interest. In both experimental and human studies, ACE inhibitors appear to perform better than other antihypertensive agents in reversing cardiac structural changes. A recent meta-analysis showed ACE inhibitors to be more efficacious than other first-line antihypertensives in reducing left ventricular mass. A controlled long-term study of previously untreated men showed that enalapril reversed LVH significantly better than did hydrochlorothiazide and that the regression of LVH was independently related to blockade of the renin-angiotensin system. Indeed, there have been studies showing that ACE inhibitors can affect LVH without lowering blood pressure. Moreover, ACE inhibitors have shown cardioprotective and cardioreparative properties in experimental models of hypertensive LVH. In conclusion, ACE inhibitors are effective in reversing LVH as well as interstitial fibrosis. The prognostic implications of this remain to be seen. So far, the experience with spirapril on LVH is limited, but the accumulated data are promising.